Phase I
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Evozyne inked a partnership with Takeda Pharmaceutical to develop next-generation gene therapies for up to four rare disease targets. Continue reading for that and more collaboration news from this week.
Speakers at the 2022 Virtual Growth Conference’s session on pancreatic cancer acknowledged the exceptional challenges while extolling advances in immune-based therapies and combination approaches.
The company’s shares rose by 29.6% on NASDAQ shortly after the announcement.
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
Although the data suggests the vaccines are extremely effective and generally safe, analysis is still coming in about adverse events as well as effectiveness in specific patient populations.
Taysha Gene Therapies announced that it will focus its efforts on clinical programs targeting Rett Syndrome and giant axonal neuropathy (GAN), resulting in a 35% reduction in its workforce.
A team at the University of California, San Diego developed a drug screening method to help determine why Alzheimer’s drugs fail. The system analyzes disease mechanisms in human neurons.
Aldeyra Therapeutics will announce three clinical trials involving ADX-629, its first-in-class oral RASP modulator, at its 2022 Research & Development Day.
PRESS RELEASES